Evidence map›Paper›PMID 31661487›Full record

ArticlePLoS medicine2019

Longitudinal engagement trajectories and risk of death among new ART starters in Zambia: A group-based multi-trajectory analysis.

Aaloke Mody, Ingrid Eshun-Wilson, Kombatende Sikombe, Sheree R Schwartz, Laura K Beres, Sandra Simbeza, Njekwa Mukamba, Paul Somwe, Carolyn Bolton-Moore, Nancy Padian and 3 more

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in PLoS medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06803316 (Optimizing Care Delivery to Support Reengagement in PLWH Returning to HIV Care After Treatment Lapses in Zambia), which is not on this map. Cited by 28 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06803316 completednot on this mapstarted 2022, after this paper: background citation

Optimizing Care Delivery to Support Reengagement in PLWH Returning to HIV Care After Treatment Lapses in Zambia

Typeobservational_patient_registrySponsorCentre for Infectious Disease Research in ZambiaRan2022 to 2025Enrolled658ConditionsHIV Antiretroviral Therapy (ART) Adherence
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Aaloke ModyDivision of HIV, ID and Global Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, California, United States of America.ORCID 0000-0003-3787-365X
Ingrid Eshun-WilsonDivision of HIV, ID and Global Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, California, United States of America.ORCID 0000-0002-4049-9868
Kombatende SikombeCentre for Infectious Diseases Research in Zambia, Lusaka, Zambia.ORCID 0000-0002-8187-8661
Sheree R SchwartzDepartment of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID 0000-0001-6090-2880
Laura K BeresDepartment of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID 0000-0002-4731-7828
Sandra SimbezaCentre for Infectious Diseases Research in Zambia, Lusaka, Zambia.ORCID 0000-0002-0150-3369
Njekwa MukambaCentre for Infectious Diseases Research in Zambia, Lusaka, Zambia.ORCID 0000-0002-5757-6858
Paul SomweCentre for Infectious Diseases Research in Zambia, Lusaka, Zambia.
Carolyn Bolton-MooreCentre for Infectious Diseases Research in Zambia, Lusaka, Zambia.ORCID 0000-0001-9103-7746
Nancy PadianDivision of Epidemiology, University of California, Berkeley, California, United States of America.
Charles B HolmesDepartment of Medicine, Georgetown University, Washington, District of Columbia, United States of America.ORCID 0000-0002-7924-6761
Izukanji SikazweCentre for Infectious Diseases Research in Zambia, Lusaka, Zambia.ORCID 0000-0002-3898-2607
Elvin H GengDivision of HIV, ID and Global Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, California, United States of America.ORCID 0000-0002-0825-1424

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
MENTORING MULTIDISCIPLINARY PATIENT-ORIENTED RESEARCH IN ENGAGEMENT IN HIV CAREK24AI134413 · NIAID · WASHINGTON UNIVERSITY · PI Elvin H. Geng · 2017 to 2026
$1.4M
Patterns and Factors Influencing Return to Care among HIV Patients in ZambiaF31MH109378 · NIMH · JOHNS HOPKINS UNIVERSITY · PI BERES, LAURA · 2016 to 2019
$157k
NIAID NIH HHS K24 AI134413NIAID NIH HHS P30 AI027763NIAID NIH HHS T32 AI060530NIMH NIH HHS F31 MH109378
6 · The paper itself

Abstract

backgroundRetention in HIV treatment must be improved to advance the HIV response, but research to characterize gaps in retention has focused on estimates from single time points and population-level averages. These approaches do not assess the engagement patterns of individual patients over time and fail to account for both their dynamic nature and the heterogeneity between patients. We apply group-based trajectory analysis-a special application of latent class analysis to longitudinal data-among new antiretroviral therapy (ART) starters in Zambia to identify groups defined by engagement patterns over time and to assess their association with mortality. METHODS AND

findingsWe analyzed a cohort of HIV-infected adults who newly started ART between August 1, 2013, and February 1, 2015, across 64 clinics in Zambia. We performed group-based multi-trajectory analysis to identify subgroups with distinct trajectories in medication possession ratio (MPR, a validated adherence metric based on pharmacy refill data) over the past 3 months and loss to follow-up (LTFU, >90 days late for last visit) among patients with at least 180 days of observation time. We used multinomial logistic regression to identify baseline factors associated with belonging to particular trajectory groups. We obtained Kaplan-Meier estimates with bootstrapped confidence intervals of the cumulative incidence of mortality stratified by trajectory group and performed adjusted Poisson regression to estimate adjusted incidence rate ratios (aIRRs) for mortality by trajectory group. Inverse probability weights were applied to all analyses to account for updated outcomes ascertained from tracing a random subset of patients lost to follow-up as of July 31, 2015. Overall, 38,879 patients (63.3% female, median age 35 years [IQR 29-41], median enrollment CD4 count 280 cells/μl [IQR 146-431]) were included in our cohort. Analyses revealed 6 trajectory groups among the new ART starters: (1) 28.5% of patients demonstrated consistently high adherence and retention; (2) 22.2% showed early nonadherence but consistent retention; (3) 21.6% showed gradually decreasing adherence and retention; (4) 8.6% showed early LTFU with later reengagement; (5) 8.7% had early LTFU without reengagement; and (6) 10.4% had late LTFU without reengagement. Identified groups exhibited large differences in survival: after adjustment, the "early LTFU with reengagement" group (aIRR 3.4 [95% CI 1.2-9.7], p = 0.019), the "early LTFU" group (aIRR 6.4 [95% CI 2.5-16.3], p < 0.001), and the "late LTFU" group (aIRR 4.7 [95% CI 2.0-11.3], p = 0.001) had higher rates of mortality as compared to the group with consistently high adherence/retention. Limitations of this study include using data observed after baseline to identify trajectory groups and to classify patients into these groups, excluding patients who died or transferred within the first 180 days, and the uncertain generalizability of the data to current care standards.

conclusionsAmong new ART starters in Zambia, we observed 6 patient subgroups that demonstrated distinctive engagement trajectories over time and that were associated with marked differences in the subsequent risk of mortality. Further efforts to develop tailored intervention strategies for different types of engagement behaviors, monitor early engagement to identify higher-risk patients, and better understand the determinants of these heterogeneous behaviors can help improve care delivery and survival in this population.

Indexed as

Medication AdherenceAdolescentAdultAgedAnti-Retroviral AgentsCD4 Lymphocyte CountDelivery of Health CareElectronic Health RecordsFemaleHIV InfectionsHumansIncidenceKaplan-Meier EstimateLatent Class AnalysisLongitudinal StudiesMaleAnti-Retroviral Agents

Identifiers

PMID31661487
PMCPMC6818762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.